Not So Different: A Podcast From The Center For Biosimilars

Show notes: To learn more about the US launch of Byooviz, click here. To read more about the anticipation for ophthalmology biosimilars, click here. To read more of Dr. Oskouei’s comments on “Round 2,” click here. To learn more about the EU approval of Byooviz, click here. To learn more about the Canadian approval of Byooviz, click here. To read more on the anticipation for aflibercept biosimilars, click here.

To listen to part 1 of this podcast, click here. To listen to part 2 of this podcast, click here. To learn more about building patient confidence in biosimilars, click here. To learn more about how education can improve patient confidence, click here.

To listen to part 1 of this podcast, click here. To learn more about building physician confidence in biosimilars, click here. For more on how switching to biosimilars can  impact budgets and savings, click here.

Despite some biosimilars, including those for filgrastim, trastuzumab, and bevacizumab, achieving a greater US market share than their originators, other biosimilar categories, such as pegfilgrastim and infliximab, are still trailing behind. Some biosimilar companies are becoming more savvy, developing new ways to make a bigger statement in the market. We sat down with Kirollos Hanna, PharmD, the manager of Oncology Pharmacy at the University of Minnesota Medical Center, an associate editor for the Journal of the Advanced Practitioner in Oncology, and an assistant professor at the Mayo Clinic School of Medicine, to discuss what tactics biosimilar companies are using to better compete alongside originator manufacturers.

A major barrier to biosimilar adoption is physician hesitancy when it comes to prescribing these agents, especially in the oncology space. Physicians often want more clinical or real-world evidence on the safety and efficacy of biosimilars compared with reference products in patients with cancer, for whom the stakes are high when choosing a therapeutic or supportive agent. Additionally, some clinicians worry about having to stock multiple biosimilars for a single reference product. These may require different storage conditions and increase the risk of administering the wrong agent, creating financial risk for the practice. We sat down with Gary Lyman, MD, MPH, an oncologist, hematologist, public health researcher, and long-time biosimilar advocate who has also helped develop guidelines in support of using biosimilars in the oncology space. We discussed what steps are needed to improve physician confidence in using biosimilars.

To hear more from Paul on biosimilar issues, click here or here. To read about Paul’s insight on the current issues in the Indian biosimilar market, click here.

To learn more about the Hatch-Waxman Act, click here. To learn more about how biosimilars compare with the generics market, click here. To learn more about the challenges that both the biosimilars and generic markets face, click here.

For background reading on the ACA case, read about the June 2021 ruling here, and for background on the withdrawal of the Department of Justice from the plaintiffs’ side of the suit, click here. 

To hear more comments from Ping Cao, click here. To learn more about Henlius’ development plans, click here. To learn more about Henlius’ approval for their adalimumab biosimilar, click here. To learn more about PD-1 inhibitors, click here.

To learn more about Sonia’s work, click here. To learn more about pharmacists’ role in promoting biosimilars, click here.

To learn more about payer preferences, click here. To see how Minnesota legislators are working to override payer preferences, click here. For more on payer influence on prescribing patterns, click here. For more on NCCN’s biosimilar work, click here.   You can also check out part 1 and part 2 of this series. To check out our Biosimilar Approvals navigator, click here.

To learn more about struggles regarding physician decisions on biosimilars, click here. For more on payer influence on prescribing patterns, click here. For more on NCCN’s biosimilar work, click here.

For more on biosimilar perception, click here.  For more on NCCN’s biosimilar work, click here.

To learn more about Brexit's impact on the biologics industry, click here.

Learn more about Dr Petit’s study.

To learn more about the bill, click here. To read the bill’s official text, click here. To learn more about payer formulary preferences, click here.

To learn more about Valenti and Cerwicki's updated guide, click here. To learn more about adalimumab patent disputes, click here. To learn more about the future state for the adalimumab market, click here. To take our quiz on adalimumab, click here. 

To learn more about phase 3 of the BC Biosimilars Initiative, click here. To learn more about recent biosimilar launches in Canada, click here or here. To learn more about biosimilar switches in Canada, click here. To learn more about other Canadian province’s biosimilar plans, click here. To learn more about Pacific Blue Cross’s success with the program, click here.

To learn more about Celltrion's EU approval, click here. To learn more about Alvotech’s high concentration adalimumab, click here. To learn more about high-concentration citrate-free adalimumab products, click here. To learn about the patent dance, click here. For more in adalimumab news, click here or here.

To learn more about BI’s citizen petition, click here. To hear more from Steven Lucio, PharmD, BCPS, click here. To learn more about Vizient, click here.